CytomX Therapeutics Inc (NASDAQ:CTMX) does about 802.52K shares in volume on a normal day but saw 826527 shares change hands in the recent trading day. The company now has a market cap of 79.82M USD. Its current market price is $1.02, marking an increase of 6.22% compared to the previous close of $0.96. The 52 week high reached by this stock is $5.85 whilst the lowest price level in 52 weeks is $0.83. The script in recent trading has seen the stock touch a high of $8 and a low of $3.25.
CytomX Therapeutics Inc (CTMX) has a 20-day trading average at $0.9745 and the current price is -82.56% off the 52-week high compared with 22.45% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.0726 and its 200-day simple moving average is $1.5827. If we look at the stock’s price movements over the week, volatility stands at 8.06%, which decreases to 7.16% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 52.61 to suggest the stock is neutral.
4 analysts observing the CytomX Therapeutics Inc (CTMX) stock have set the 12-month price targets for the company’s shares at between $3.25 and $8. The consensus objective for the share price is $5.29, suggesting that the stock has a potential upside of 80.72% over the period. The median price target is 82.53% away from the current levels at $5.84.
FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 28, 2024 when Piper Sandler upgraded the stock to “Overweight” and issued a price target of between $2.25 and $3.50. Wedbush also upgraded the stock to “Outperform” from Neutral on May 09, 2024 at a price target of $8. Jefferies upgraded its price target at $2.50-$8.
The current price level is 4.65%, -4.91%, and -35.55% away from its SMA20, SMA50, and SMA200 respectively, with the CTMX price moving above the 50-day SMA on current market day. CytomX Therapeutics Inc (CTMX) stock is up 14.26% over the week and 0.99% over the past month. Its price is -34.19% year-to-date and -23.31% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/30/2024, with the company’s earnings per share (EPS) of 0.01 above consensus estimates by 0.04. The company’s next earnings report forecasts estimating quarterly EPS at -0.13 and 0.06 for whole year. Expected sales for next quarter are $18.5M, which analysts say will come at $115.72M for the current fiscal year and next year at $80.57M. In addition, estimates put the company’s current quarterly revenue at an average of $13.53M.
Its 12-month price target is $5.84. To reach the target analysts have set, the stock logically needs to grow 80.72 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3.25, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $8.
Outstanding shares total 78.26M with insiders holding 1.00% of the shares and institutional holders owning 65.62% of the company’s common stock. The price to earnings ratio (P/E ratio) amounts to 6.01. The beta has a value of 1.04. Price to sales ratio is 0.63.
